John Kulp lll, Ph.D. appointed regional assistant dean for Doylestown campus of School of Graduate Studies

Tuesday, January 10, 2017

johnkulpScott Koerwer, Ed.D. vice dean for graduate studies, School of Graduate Studies at the Geisinger Commonwealth School of Medicine (Geisinger Commonwealth), recently announced the appointment of John Kulp lll, Ph.D. to the position of regional assistant dean for the Doylestown campus of Geisinger Commonwealth’s School of Graduate Studies.

In his role as regional assistant dean, Dr. Kulp will oversee all aspects of the graduate student educational experience at Geisinger Commonwealth’s Doylestown campus, including curriculum delivery, student support, career path development and academic integrity. Dr. Kulp was instrumental in establishing the Doylestown campus, housed in the Pennsylvania Biotechnology Center in Bucks County, an incubator for more than 40 biotech start-up companies. The Doylestown campus offers a place for graduate students in various life-sciences-related academic disciplines to learn alongside of and interact with preeminent scientists and entrepreneurs in a distinct learning environment not duplicated anywhere else in the region.

Dr. Kulp’s background is in the field of bioorganic chemistry and his vision is to create better drugs by rigorous molecular design.  He earned a B.A. in chemistry from Drew University and an M.S. degree and a Ph.D. from New York University. He received further post-doctoral training at the Naval Research Laboratory in Washington, D.C., where he patented a new class of helical peptide architectures and was appointed a federal staff scientist. In 2010, he joined BioLeap, a small business with a proprietary fragment-based computational chemistry software platform specializing in protein-protein interactions. From 2013 to 2014, he was the project leader for BioLeap’s PCSK9 program, which consisted of modeling, assays and chemical synthesis — work done in conjunction with partners including MIT and Harvard. In 2014, he founded Conifer Point Pharmaceuticals, a computational technology company to help accelerate medicinal chemistry projects and increase customer success. Conifer Point was recently awarded an NIH SBIR phase I grant to develop a cloud-based platform for molecular design, thus helping accelerate preclinical drug discovery. In addition to his position with Geisinger Commonwealth, Dr. Kulp is an associate professor in the Department of Medicinal Chemistry and the director of academic affairs at Baruch S. Blumberg Institute, Doylestown.

TCMC Media Contact:

Elizabeth Zygmunt
Director of Media and Public Relations 
Office: 570-504-9687
On Call: 570-687-9703

Geisinger Commonwealth School of Medicine is committed to non-discrimination in all employment and educational opportunities.